Joint Clinical Trials Office

You are here

AtRial Cardiopathy and Antithrombotic Drugs In prevention After Cryptogenic stroke (ARCADIA)

Clinical Trial Details

This is a randomized trial taking place at multiple sites, intervening with patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Patients will be followed for a minimum of 1.5 years and will be randomized to either take aspirin as the stroke intervention or apixaban, which is currently only prescribed to stroke patients that also have atrial fibrillation. This trial seeks to study the effectiveness of aspirin vs. apixaban in preventing recurrent stroke. 

Key Eligibility: 
  • Men and women 45 years of age or older.
  • Clinical diagnosis of ischemic stroke
  • Unknown cause of stroke
  • No history of atrial fibrillation
  • No known allergy or intolerance to aspirin or apixaban
  • Detailed eligibility will be reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carla Sherman
(646) 962-8284
cas9149@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1710018712

ClinicalTrials.gov:

NCT03192215

Status

Open to Enrollment

Age Group

Adult

Sponsor

Disease